Covid19
Conditions
Brief summary
Phase 1: 25 patients with a PCR-based diagnosis of Covid-19 will be be included to give 500 microliters of saliva and a 3 ml sample of blood for proteomic analysis; a drop of blood will also be put in a device connected to a silica matrix to perform spectrometric analyses. 25 patients with a non-Covid-19 respiratory infection will be included for the same samples. The proteomic analyses will be performed from classicaly draught blood, blood drop on silica, and saliva, to search for discriminating profiles between Covid-19 and non-Covid-19. Phase 2: 150 patients with a suspected Covid-19 will be included at the same time than the Covid-19PCR is performed ; they will have a sample of saliva and of a drop of blood for proteomic analysis, whose results will be matched with PCR results.
Detailed description
Phase 1: derivation analyses 25 patients with a PCR-based diagnosis of Covid-19 will be be included to give 500 microliters of saliva and a 3 ml sample of blood for proteomic analysis; a drop of blood will also be put in a device connected to a silica matrix to perform spectrometric analyses. 25 patients with a non-Covid-19 respiratory infection will be included for the same samples. The proteomic analyses will be performed from classicaly draught blood, blood drop on silica, and saliva, to search for discriminating profiles between Covid-19 and non-Covid-19. Phase 2: confirmation analyses 150 patients with a suspected Covid-19 will be included at the same time than the Covid-19PCR is performed ; they will have a sample of saliva and of a drop of blood for proteomic analysis, whose results will be matched with PCR results.
Interventions
DEVICEsample of blood and saliva
sample of 3ml of blood by veinous puncture, of 1 drop of blood by needlestick, and of saliva by spitting
Sponsors
University Hospital, Grenoble
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
phase 1: patients with Covid-19 or with anotther respiratory infection phase 2 : patients with a supsected Covid-19
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
phase 1: Inclusion Criteria for group 1: * positive Covid-19 PCR * clinical signs evocative of Covid-19
Exclusion criteria
for group 1: * asymptomatic Covid-19 infection Inclusion Criteria for group 1: * negative Covid-19 PCR * acute respiratory infection
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Feasibility of proteomic profile | one day | MALDI-TOF mass spectrometric analysis of blood and saliva proteins to obtain a specific proteomic profile (obtained or not) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Interest of proteomic profile | one day | Correlation between spectral analysis and severity of pathology at admission. |
| Stability of proteomic profile | two days | Evaluation of mass spectrometric analysis reproductibility 48 hours after ambiant temperature conservation |
Countries
France
Outcome results
None listed